3 nd International Conference LEUKEMIA 2014 Santa Margherita Ligure (Italy) May, 21-24, 2014 With the patronage of: Società Italiana di Ematologia - SIE Società Italiana di Ematologia Sperimentale - SIES Gruppo Italiano Trapianto Midollo Osseo - GITMO Associazione Malattie del Sangue - AMS Associazione Ricerche Emato-Oncologiche - AREO
[ Presentation ] The Conference, with the participation of the most important international and Italian experts, wants to provide an update on the most innovative aspects of cell biology, molecular biology and treatment of acute and chronic leukemias, myelodysplastic syndromes and chronic myelodysplasia. One section will be dedicated to the new drugs in onco-hematology. [ Preliminary Program ] Wednesday, May 21 NEW DRUGS IN ONCO-HEMATOLOGY (not for CME credits) Chairmen: Massimo Federico, Pier Luigi Zinzani 14.00 tbd James Carmichael 14.15 Novelties in strategic approach to chronical hematological malignancies Alf Bernhardt 14.30 tbd Andreas Engert 14.45 tbd Giovanni Martinelli 15.00 tbd Giuseppe Rossi 15.15 tbd Daniele Alberti 15.30 The use of an adaptive trial design in a phase III trial of vosaroxin and cytarabine in relapsed and refractory AML Adam Craig CHALLENGES IN PHILADELPHIA-POSITIVE LEUKEMIAS Chairmen: John M. Goldman, Angelo M. Carella 16.00 Introduction John M. Goldman 16.05 Current clinical options in Ph+ ALL Robin Foà 16.20 Early and deep molecular response predictive of long term outcome in Ph+ leukemias Giovanni Martinelli 16.35 Ponatinib : bridge to transplant and post transplant clinical strategies Fabio Ciceri 16.50 Conclusions Angelo M. Carella 17.15 Round Table BONE MARROW TRANSPLANTATION IN LEUKEMIAS: NEW PERSPECTIVES Chairmen: Andrea Bacigalupo, Alberto Bosi Immunologic pressure after transplant and HLA Fabio Ciceri Unrelated donor transplant for leukemia 2014 Jane F. Apperley
Finding a donor for most eligible patients William Arcese HDCT in MDS: indications, timing and optimization of the results. What's new? Emanuele Angelucci 18.30 End of session Thursday, May 22 8.00 Opening Ceremony ACUTE MYELOID LEUKEMIAS IN 2014: SOME UNRESOLVED ISSUES Chairmen: Jacob M. Rowe, Sergio Amadori 8.15 Introduction Jacob M. Rowe 8.20 The increasing role of mutations and genomics in AML Brunangelo Falini 8.40 The increasing clinical relevance of minimal residual disease Gert J. Ossenkoppele 9.00 Is the role of adjunctive therapy to standard 3+7? Alan K. Burnett 9.20 Optimal non-transplant post remission therapy Jacob M. Rowe 9.40 Allogeneic transplant for older patients with AML: GITMO experience Alessandro Rambaldi 10.00 Therapy of a fit 70 years old individual with AML Richard F. Schlenk 10.20 APL in 2014: next challenges for the final cure Francesco Lo Coco 10.40 Conclusions Sergio Amadori 10.45 Coffee break 11.00 Plenary Lecture Regulation of self renewal in cancer stem cells Pier Giuseppe Pelicci Presented by: Roberto Lemoli SEPSIS AND SEPTIC SHOCK IN HEMATOLOGICAL NEOPLASIAS Chairmen: Andrea Bacigalupo, tbd 11.30 Pathophysiology and clinical features Valerio Del Bono 11.45 Infections with multidrug-resistant pathogens Gian Maria Rossolini 12.00 IgM concentrated: rationale for its use in hematology in the era of "bad bugs" Fabio Tumietto
12.45 IgM enriched immunoglobulins (Pentaglobin) and defribotide in the prophylaxis of toxicity after allogenic hematopoietic transplantation in acute leukemia Giuseppe Milone 12.30 Lunch CHRONIC LYMPHOCYTIC LEUKEMIA Chairmen: Giovanni Pizzolo, Enrica Morra 15.00 Introduction Manlio Ferrarini 15.05 NoTCH1 mutations: pathogenesis and clinical significance Davide Rossi 15.25 Transforming response prediction to chemo-immunotherapy using genome technologies Anna Schuh 15.45 Do the next molecular markers have an impact in treatment strategy? Gianluca Gaidano 16.05 First line therapy: what are the options today? Marco Montillo 16.25 Ultra-high risk patients: definition and treatment pathway in the era of novel drug landscape Peter Dreger 16.45 Break 17.00 Second line therapy: what are the options today? Leblond Véronique 17.20 Immunotherapeutic strategies including transplant John G. Gribben 17.40 A look at the future: new options? George Follows 18.00 Conclusions Giovanni Pizzolo 18.00 End of session Friday, May 23 PH-NEGATIVE MYELOPROLIFERATIVE SYNDROMES Chairmen: Tiziano Barbui, Marco Gobbi 8.00 Introduction Tiziano Barbui 8.05 Molecular diagnosis of MPNs in practice Robert Kralovics 8.25 Molecular prognostic profiling in MF Alessandro Vannucchi 8.45 Therapeutic challenges in PV and ET patients conventionally classified at low-risk for thrombosis Tiziano Barbui 9.05 Prefibrotic MF: a diagnosis that counts Giovanni Barosi
9.25 Are we ready for treatment recommendations with ruxolitinib in myelofibrosis? Jean-Jacques Kiladjian 09.45 Deciding hematopoietic stem-cell transplant in myelofibrosis Nicolaus Kröger 10.05 Conclusions Marco Gobbi 10.10 Coffee break NEW MOLECULAR INSIGHTS AND THERAPEUTIC STRATEGIES IN ACUTE LYMPHOCYTIC LEUKEMIA Chairmen: Dieter Hoelzer, Felicetto Ferrara 10.30 Introduction Dieter Hoelzer 10.35 New markers for the diagnosis of ALL: including NGS? Robin Foà 10.55 Minimal residual disease: comparison of different methods Monika Brüggemann 11.15 Current treatment results without antibodies Renato Bassan 11.35 Antibody therapy Dieter Hoelzer 11.55 Targeted therapy Oliver G. Ottmann 12.15 Therapy oft-all: what can we learn from other T-cell neoplasies? Pier Luigi Zinzani 12.35 Risk factors in adult T-ALL Vahid Asnafi 12.55 Stem cell transplantation Andrea Bacigalupo 13.15 Conclusions Roberto Foà 13.20 Lunch MYELODYSPLASTIC SYNDROMES Chairmen: Giorgina Specchia, tbd 15.00 Introduction Giorgina Specchia 15.05 Classification tbd 15.25 Prognostic models to predict survival Valeria Santini 15.45 Low-risk patients with deletions in chromosome 5 Esther Oliva 16.05 Therapeutic strategies tbd
16.25 Five years after azacitidine approval: remaining challenges Thomas Prebet 16.45 Who and when in the course of the disease to transplant classification Maria Teresa Voso 17.05 Conclusions tbd Saturday, May 24 CHRONIC MYELOID LEUKEMIAS: WHAT IS NEW? Chairmen: John M. Goldman, Angelo M. Carella 8.00 Introduction Angelo M. Carella 8.05 The bases for clinical heterogeneity Giuseppe Saglio 8.25 Initial choice of therapy Michele Baccarani 8.45 Molecular monitoring Andreas Hochhaus 9.05 Alternative approaches in eradicating the malignant clone Richard A. Van Etten 9.25 Early molecular response is predictive of long-term outcome? Susan Branford 9.45 Coffee break 10.00 Current clinical options after resistance/intolerance to 1G/2G TKIs Fabrizio Pane 10.20 Safety profiles of different TKIsC Carlo Gambacorti-Passerini 10.40 IFN: "new ways with old remedies?" Rudiger Hehlmann 11.00 When should we transplant? Jane Apperley 11.20 How we will manage CML in the next decade? Stephen O'Brien 11.40 Conclusions John M. Goldman 12.00 End of the conference [ Adressed to ] Physicians specialized in Hematology, Oncology and Biologists.
[ Scientific Coordinators ] Angelo Michele Carella U.O.C. Ematologia I IRCCS A.O.U. San Martino-IST Genoa (I) Felicetto Ferrara U.O. Ematologia con Trapianto di Midollo Osseo A.O. A. Cardarelli Naples (I) Enrica Morra U.O. Ematologia e Trapianti di Midollo A.O. Ospedale Niguarda Cà Granda Milan (I) [ Speakers and Chairmen ] Daniele Alberti Novartis Farma Origgio, MI (I) Sergio Amadori U.O.C. Ematologia Policlinico Tor Vergata Roma (I) Emanuela Angelucci U.O. Ematologia e Centro Trapianti Midollo Osseo Ospedale "Armando Businco" Azienda USL 8 Cagliari (I) Jane F. Apperley Departmento of Haematology Hammersmith Hospital Imperial College London London (UK) William Arcese Dipartimento di Biopatologia e Diagnostica per Immagini Università di Tor Vergata Roma (I) Vahid Asnafi Department of Hematology Hôpital Necker-Enfants Malades Université Paris-5 Descartes Paris (F) Michele Baccarani Department of Hematology/Oncology L. e A. Seragnoli University of Bologna S. Orsola-Malpighi Hospital Bologna (I) Andrea Bacigalupo Divisione di Ematologia e Trapianto di Midollo Osseo IRCCS A.O.U. San Martino-IST Genova (I)
Tiziano Barbui U.O. di Ematologia A.O. Ospedali Riuniti Bergamo(I) Giovanni Barosi I Clinica Medica Fondazione IRCCS Policlinico San Matteo Pavia (I) Renato Bassan Ospedale dell'angelo Azienda ULSS 12 Veneziana Venezia Mestre (I) Alf Bernhardt Hematological Franchise Roche Basel (CH) Alberto Bosi Cattedra di Ematologia Università degli Studi Firenze (I) Susan Branford Department of Genetics and Molecular Pathology Centre for Cancer Biology Adelaide (AUS) Monika Brüggemann Department of Hematology University Hospital Schleswig-Holstein Kiel (D) Alan K. Burnett School of Medicine Cardiff University Cardiff (UK) James Carmichael Celgene Institute Translational Research Europe Seville (S) Adam Craig Development and Medical Officer Sunesis Pharmaceuticals, Inc South San Francisco (USA) Fabio Ciceri Divisione di Ematologia e BMT Istututo Scientifico San Raffaele Milano (I) Valerio Del Bono U.O. Malattie Infettive IRCCS A.O.U. San Martino-IST Genoa (I) Peter Dreger Department of Medicine V University of Heidelberg Heidelberg (D)
Andreas Engert Department of Internal Medicine I German Hodgkin Study Group University Hospital Cologne (D) Brunangelo Falini Cattedra di Ematologia Università - Policlinico Monteluce Perugia (I) Massimo Federico Centro Oncologico Modenese A.O. di Modena Modena (I) Manlio Ferrarini Direzione Scientifica IRCCS A.O.U. San Martino-IST Genova (I) George Follows Cambridge University Hospitals NHS Foundation Trust University of Cambridge Cambridge (UK) Robin Foà Dip. di Biotecnologie Cellulari Ematologia Università "La Sapienza" Roma (I) Gianluca Gaidano A.S.O. Maggiore della Carità Università del Piemonte Orientale Amedeo Avogadro Novara (I) Carlo Gambacorti-Passerini A.O. San Gerardo Università degli Studi di Milano Bicocca Monza (I) Marco Gobbi Clinica di Ematologia IRCCS A.O.U. San Martino-IST Genova (I) John M. Goldman Department of Haematology Imperial College London London (UK) John G. Gribben Bart's Cancer Institute Queen Mary University of London London (UK) Rudiger Hehlmann III Medizinische Klinik Ruprecht-Karls-Universität Heidelberg (D)
Andreas Hochhaus Klinik für Innere Medizin II Universitätsklinikum Jena Jena (D) Dieter Hoelzer Medizinische Klinik III University Hospital Frankfurt (D) Jean-Jacques Kiladjian Centre d'investigations Cliniques Saint-Louis Hospital and Paris Diderot University Paris (F) Robert Kralovics CeMM Research Center for Molecular Medicine Medical University of Vienna Vienna (A) Nicolaus Kröger Center for Stem Cell Transplantation University Medical Center Hamburg (D) Véronique Leblond Department of Hematology Hôpital Pitié-Salpêtrière APHP Paris (F) Roberto M. Lemoli Clinica di Ematologia Dipartimento di Medicina Interna e Specialità Mediche - DiMI IRCCS A.O.U. San Martino-IST Genova (I) Francesco Lo Coco Dipartimento di Biopatologia e Diagnostica per immagini Università di Tor Vergata Roma (I) Giovanni Martinelli Istituto di Ematologia e Oncologia Medica "L. A. Seragnoli" Università degli Studi - A.O. di Bologna Policlinico S. Orsola-Malpighi Bologna (I) Giuseppe Milone Divisione Clinicizzata di Ematologia Ospedale Ferrarotto Catania (I) Marco Montillo U.O. di Ematologia e Trapianti di Midollo A.O. Niguarda Ca' Granda Milano (I) Stephen O'Brien Northern Institute for Cancer Research Newcastle University Medical School Newcastle (UK)
Esther Natalie Oliva Divisione di Ematologia A.O. Bianchi Melacrino Morelli Reggio Calabria (I) Gert J. Ossenkoppele Department of Haematology VU University Medical Centre Amsterdam (NL) Oliver G. Ottmann Department of Hematology and Oncology Goethe University Frankfurt (D) Fabrizio Pane U.O. Ematologica e trapianti di midollo A.O.U. Policlinico Napoli (I) Pier Giuseppe Pelicci Dipartimento di Oncologia Sperimentale Istituto Europeo di Oncologia (IEO) Milano (I) Giovanni Pizzolo Dipartimento Medicina Clinica e Sperimentale Policlinico "G.B. Rossi" Verona (I) Thomas Prebet Hematology Department Institut Paoli-Calmettes and Aix-Marseille Université Marseille (F) Alessandro Rambaldi U.S.C. di Ematologia A. O. Ospedali Riuniti Bergamo (I) Davide Rossi Dipartimento di Medicina Clinica e Sperimentale Università del Piemonte Orientale Amedeo Avogadro Novara (I) Giuseppe Rossi U.O. Ematologia A.O. Spedali Civili Brescia (I) Gian Maria Rossolini Dipartimento Biotecnologie Mediche Università degli Studi Siena (I) Jacob M. Rowe Department of Haematology Shaare Zedek Medical Centre Jerusalem (IL)
Giuseppe Saglio U.O. Direz. Universitaria Medicina Interna II A.S.O. San Luigi Orbassano, TO, (I) Valeria Santini Unità Funzionale di Ematologia A.O.U. Careggi Firenze (I) Richard F. Schlenk Department of Internal Medicine III University Hospital of Ulm Ulm (D) Anna Schuh NIHR Biomedical Research Centre University of Oxford Oxford (UK) Giorgina Specchia Cattedra di Ematologia Università degli Studi - Policlinico Bari (I) Fabio Tumietto Istituto di Malattie Infettive A.O. di Bologna - Policlinico S. Orsola-Malpighi Bologna (I) Richard A. Van Etten Molecular Oncology Research Institute Division of Hematology/Oncology Tufts Medical Center Boston (USA) Alessandro M. Vannucchi Unità Funzionale di Ematologia Università degli Studi di Firenze Firenze (I) Maria Teresa Voso Istituto di Ematologia Università Cattolica Sacro Cuore Roma (I) Pier Luigi Zinzani Istituto di Ematologia ed Oncologia Medica Università - A.O. di Bologna Policlinico S. Orsola-Malpighi Bologna (I) [ Venue ] Grand Hotel Miramare Via Milite Ignoto, 30 Santa Margherita Ligure (GE), Italy